Evgen Pharma PLC Share Option Exercise and Issue of Equity (6039Z)
21 Maggio 2019 - 8:00AM
UK Regulatory
TIDMEVG
RNS Number : 6039Z
Evgen Pharma PLC
21 May 2019
For immediate release
Evgen Pharma plc
("Evgen" or "the Company")
Share option exercise and issue of equity
Evgen (AIM: EVG), a clinical stage drug development company
focused on the treatment of cancer and neurological conditions,
announces that it has received notice to exercise options over
321,600 ordinary shares in the Company.
Options over 321,600 shares were exercised pursuant to grants
under individual option agreements with an exercise price of 0.875p
per share. Accordingly, the Company has issued and allotted 321,600
new ordinary shares of 0.25 pence each ("New Ordinary Shares"). The
New Ordinary Shares rank pari passu with the Company's existing
issued ordinary shares. Application has been made to admit the New
Ordinary Shares to trading on AIM and dealings in these shares are
expected to commence at 8.00 a.m. on 24 May 2019.
There are no shares held in treasury, therefore following the
admission of the New Ordinary Shares the total number of voting
rights in the Company will be 132,646,263. This figure may be used
by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest under the
Disclosure and Transparency Rules.
Enquiries:
Evgen Pharma plc
Dr Stephen Franklin, CEO c/o +44 (0) 20 7466 5000
Richard Moulson, CFO
www.evgen.com
finnCap
Geoff Nash, Teddy Whiley (Corporate
Finance)
Alice Lane, Manasa Patil (ECM)
www.finncap.com +44 (0) 20 7220 0500
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Buchanan
Mark Court, Sophie Wills, Tilly
Abraham
evgen@buchanan.uk.com +44 (0) 20 7466 5000
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company whose
lead programmes are in breast cancer and subarachnoid haemorrhage,
a type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen Pharma commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office is at the Liverpool Science Park, Liverpool. It joined the
AIM market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEPGUQGAUPBGAU
(END) Dow Jones Newswires
May 21, 2019 02:00 ET (06:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ott 2023 a Ott 2024